Mitochondrial Health and Dysfunction: A Common Concern in Chronic and Autoimmune Disorders

I. INTRODUCTION

Mitochondria, also described as the “powerhouse of the cell,” are double-membraned cell organelles that are required for both health regulation and disease progression. Mitochondria are the primary sites for aerobic respiration and energy production in eukaryotes. Over the last 20 years, there has been a growing recognition of mitochondrial function in health and disease. Most of the diseases in society are associated with mitochondrial dysfunction and disturbances in cellular bioenergetics. However, the pathophysiology and etiology of mitochondrial dysfunction in various disorders remain unclear. A complex interplay of factors, including infections, aging, mitochondrial DNA (mtDNA) mutations, physical inactivity, and sedentary lifestyle, has been studied to be the key drivers behind mitochondrial dysfunction in many common pathologies, like fibromyalgia and chronic fatigue syndrome (1). Moreover, disruptions in mitochondrial dynamics also influence the development of autoimmune conditions, such as multiple sclerosis and rheumatoid arthritis, among others.

Multiple sclerosis (MS) is a chronic autoimmune disorder in which the immune system attacks the central nervous system, specifically targeting the myelin sheath insulating nerves in the brain and spinal cord. It results in a wide spectrum of symptoms affecting cognitive, emotional, motor, sensory, and visual functions, with difficulty in walking, numbness, weakness, muscle stiffness, fatigue, and depression. On a global scale, the data show an alarming trend, with the number of affected people rising from 2.3 million in 2013 to 2.8 million in 2020, and reaching 2.9 million in 2023. While the WHO estimates over 1.8 million people are affected, the more comprehensive Atlas of MS data suggests the actual prevalence may be significantly higher, with the disease being more common in young to middle-aged adults, especially females (2) (3).

Rheumatoid arthritis (RA) is a systemic autoimmune disorder that involves immune-mediated inflammatory processes primarily targeting the synovial joints, leading to progressive joint destruction and significant disability. In the year 2019, 18 million people around the world were affected by RA. Approximately 70% of people living with this condition are women, and 55% are older than 55 years. The physical impact of the condition is widespread, with 13 million people having moderate to severe symptoms (4).

Fibromyalgia is a chronic disorder that causes widespread musculoskeletal pain, fatigue, sleep disturbances, cognitive dysfunction, and psychiatric symptoms such as anxiety and depression, significantly impacting the quality of life and daily functioning. Fibromyalgia affects approximately 2% to 3% of the population in the United States and other countries, with diagnosis rates increasing with age. It is mostly prevalent in women between 20 to 55 years of age, serving as the primary cause of musculoskeletal pain in women. In fact, adult women are twice as likely as men to be diagnosed with this condition. Fibromyalgia is very common in specialized medical settings, where over 40% of patients in tertiary pain clinics meet the criteria for diagnosis. Furthermore, people living with rheumatic disease have a higher risk of developing fibromyalgia over a period of time (5).

Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis, is a complex disorder involving chronic fatigue, sleep disturbances, post-exertional malaise, cognitive dysfunction, and orthostatic intolerance for at least 6 months. The National Institutes of Health recognizes CFS as one of the ten chronic pain conditions (6). The global prevalence of CFS is estimated to be between 0.2% and 2.8%, and in European countries, it ranges from 0.1% to 2.2% (7). Similar to any other chronic illness, people living with CFS often suffer from depression, stress, and anxiety. Although it is not a psychological disorder, CFS can be extremely debilitating.

This white paper examines the pathophysiology and root causes of these diseases through the lens of mitochondrial health. It defines how a functional nutrition-based approach can mitigate cellular dysfunction, restore metabolic stability, and significantly enhance the quality of life.

II. PATHOPHYSIOLOGY WITH RESPECT TO MITOCHONDRIAL DYSFUNCTION

A. Multiple Sclerosis (MS)

MS is recognized as a demyelinating disease of the central nervous system, which is predominantly inflammatory in origin. However, emerging evidence demonstrates that mitochondrial dysfunction is a major pathophysiological mechanism linking inflammation, demyelination, and progressive neurodegeneration, leading to irreversible disability in MS patients. Although current immunomodulatory treatments reduce relapse rates, they do not correct the processes causing neurodegeneration. Consequently, understanding how mitochondrial dysfunction contributes to the progression of MS is important.

- **Energy Metabolism Impairment**

Mitochondrial dysfunction in MS is primarily expressed as impaired energy production due to dysfunction of the mitochondrial respiratory chain. It has been repeatedly shown that the activity of the mitochondrial respiratory chain complexes, especially complex IV, is decreased in MS patients. This energy deficit will create a condition referred to as “virtual hypoxia” in demyelinated axons, where the amount of oxygen remains normal, but the energy required to meet the additional requirements of the demyelinated axons cannot be met due to the impaired mitochondrial function. The energy deficit will further impair neuronal function, including ion pumping, neurotransmitter recycling and axonal transport.

- **Oxidative Stress and Reactive Oxygen Species (ROS)**

A major form of mitochondrial dysfunction related to multiple sclerosis is oxidative stress. Mitochondria are both sources and targets of mitochondrial oxidative stress and therefore create a vicious cycle of oxidative damage. One of the most important mediators of this vicious cycle is p66ShcA, a redox enzyme that mediates mitochondrial ROS production. Studies suggest that genetic inactivation of p66Shc results in neuroprotection in experimental autoimmune encephalitis (EAE) models. This oxidative stress also results in damage to mitochondrial DNA, proteins, and lipids, leading to impaired mitochondrial function and exacerbated neurodegenerative processes.

- **Calcium Dysregulation**

Aberrant mitochondrial calcium handling plays a key role in multiple sclerosis pathophysiology. Pathological opening of the mitochondrial permeability transition pore (PTP) due to ROS and calcium overload is responsible for mitochondrial swelling, rupture of the outer mitochondrial membrane, and the release of pro-apoptotic factors. This is particularly catastrophic for demyelinated axons as redistribution of sodium channels along the axolemma increases both energy demand and calcium influx, creating a perfect storm for mitochondrial failure leading to axonal degeneration.

B. Rheumatoid Arthritis (RA)

RA is an autoimmune inflammatory condition that is defined by chronic synovial inflammation and destruction of the joints. Recent studies have shown that one major cause of RA is mitochondrial dysfunction in immune and non-immune cells, which form a loop of cycling inflammation and tissue destruction, causing permanent disabilities in RA patients.

- **Energy Metabolism Impairment**

Mitochondrial dysfunction in patients with RA involves impaired energy production due to deficiencies in the respiratory electron transport chain. Study and analysis of patient-derived blood cells demonstrate substantial reductions in both ATP production and mitochondrial membrane potential, indicating severe failure of energy production. This energy deficit induces a pathological state of metabolic crisis in multiple cell types, especially fibroblast-like synoviocytes (FLS) and immune cells, because the energy required for the activated inflammatory response cannot be met due to mitochondrial dysfunction. The failure in energy production, thus, affects essential cellular functions (such as ion pump activity, protein synthesis, and cell repair) and ultimately contributes to the pathological characteristics associated with RA.

- **Oxidative Stress and ROS**

Chronic oxidative stress associated with RA is also a key factor contributing to mitochondrial pathology in this condition. Mitochondria function as both the primary generator and the most vulnerable target of ROS, creating a vicious cycle of oxidative damage. ROS accumulation and mtDNA damage likely play a significant role in the progression of RA by further enhancing inflammation, angiogenesis, and bone destruction. Oxidative stress can damage mtDNA, proteins, and lipids, which can lead to mitochondrial dysfunction and activate inflammatory processes via redox-sensitive pathways and inflammasome activation. Increased mitochondrial ROS production also serves as a signaling mechanism to continue the inflammatory response and injure surrounding tissues.

- **Calcium Dysregulation and Mitochondrial Dynamics**

In patients with RA, mitochondrial calcium dysregulation represents a critical pathophysiological mechanism contributing to joint destruction. In fibroblast-like synoviocytes (FLS), the Mitochondrial Calcium Uniporter (MCU) is upregulated, mediating an excessive influx of calcium into the mitochondria, thereby causing mitochondrial dysfunction. This triggers the release of mtDNA and other pro-inflammatory molecules from the mitochondria into the synovial fluid, causing the mtDNA and pro-inflammatory molecules to act as damage-associated molecular patterns (DAMPs). These DAMPs contribute to the chronic inflammation associated with rheumatoid arthritis. The resulting bioenergetic crisis and inflammation create an aggressive tumour-like phenotype of FLS that invades and destroys nearby bone and cartilage, ultimately causing irreversible joint deformities.

C. Fibromyalgia

Mitochondrial dysfunction is a major contributor to fibromyalgia and leads to functional impairment of energy metabolism, oxidative stress, and an impediment to the chronic pain that characterizes this condition. Thus, the emerging evidence has changed the perception of fibromyalgia from primarily being a central sensitization disease to identifying it as a systemic disease with bioenergetic characteristics and involvement of the mitochondria.

- **Energy Metabolism Impairment**

The most obvious clinical manifestation of mitochondrial dysfunction in fibromyalgia is compromised energy production and bioenergetic failure. Studies using the Bioenergetic Health Index (BHI) in individuals diagnosed with fibromyalgia have found significant reductions in mitochondrial function, indicating that mitochondrial dysfunction in fibromyalgia correlates with the severity of the condition and the widespread pain index. The resulting energy deficit leads to a chronic cellular energy crisis, especially in muscle tissue and the CNS, where high-energy requirements for pain processing and muscle use cannot be met due to mitochondrial dysfunction (8).

The bioenergetic compromise is accompanied by decreased ATP production and phosphocreatine levels, as well as reduced oxidative phosphorylation efficiency. Several studies using microdialysis or magnetic resonance spectroscopy have demonstrated that muscle energy metabolism is altered in patients with fibromyalgia, including a marked decrease in blood flow and metabolic abnormalities in the muscles affected. The energy failure causes significant impairment in other critical cellular functions, such as ion transport, neurotransmitter recycling, and muscle contraction-relaxation cycles, and thus, contributes to the symptoms of fatigue, pain, and cognitive dysfunction (9).

- **Oxidative Stress and ROS**

Fibromyalgia is characterized by chronic oxidative damage and increased ROS, which are caused by mitochondrial dysfunction. Studies reveal that fibromyalgia patients have elevated oxidative stress biomarkers and disrupted thiol/disulfide homeostasis, indicating systemic oxidative damage. Excessive ROS generation due to mitochondrial impairment creates a cycle of ROS that further damages the mitochondria and their components, causing more cellular dysfunction. In addition, an increase in ROS damages cellular structures, activates inflammatory pathways, and makes pain

receptors more sensitive, perpetuating the chronic pain associated with fibromyalgia (10).

- Impaired Mitochondrial Dynamics and Biogenesis

Several factors are known to have an impact on mitochondrial dynamics in fibromyalgia. Impaired biogenesis, defective mitophagy, and altered quality control mechanisms are some of the key disturbances that occur within the mitochondria. The ratio of mitochondrial mass to autophagy levels has been suggested as a potential biomarker for fibromyalgia diagnosis and disease monitoring. Research conducted on patients with fibromyalgia has revealed that there is also an imbalance between the mechanisms that regulate and maintain mitochondrial homeostasis, along with disrupted mitochondrial turnover and accumulation of dysfunctional organelles. This impairment in mitochondrial quality control mechanisms contributes to the chronic nature of fibromyalgia. Additionally, reversing or restoring the normal dynamics of mitochondria has emerged as a potential target for future interventions; specifically, those aimed at enhancing mitochondrial biogenesis as well as mitophagy.

D. Chronic Fatigue Syndrome (CFS)

CFS is a multi-faceted, debilitating condition where patients suffer from fatigue that isn't alleviated with rest and can worsen from either physical and/or mental exertion. While multiple proposed pathophysiological mechanisms underlie CFS, mitochondrial dysfunction appears to be one of the most prominent contributory factors to disease progression by providing a biochemical rationale for the extreme energy deficits seen in patients.

- **Impaired Oxidative Phosphorylation and ATP Production**

The primary defect in CFS can be attributed to impaired oxidative phosphorylation, which implicates the mitochondrial process responsible for producing ATP via the electron transport chain. Studies have revealed that patients with CFS have decreased levels of ATP production as well as increased levels of oxidative stress, and the resultant differential protein expression patterns indicate that there are impairments in mitochondrial function. Bioenergetic impairments are notably apparent in patients' peripheral blood mononuclear cells (PBMCs), as proteomic assessments of CFS patients have shown significant deviation from normal with respect to proteins involved in oxidative phosphorylation (11). Another important finding reveals dysfunction of complex V (ATP synthase). Studies have identified an isolated Complex V inefficiency in immortalized lymphocytes from CFS patients, resulting in impaired ATP production despite the mitochondrial respiratory capacity being compensatorily upregulated.

Although these adaptations may restore resting ATP levels, they seem insufficient to meet acute energy demands, potentially explaining the characteristic symptoms of fatigue and post-exertional malaise associated with CFS (12).

- Oxidative and Nitrosative Stress Pathways

Mitochondrial dysfunction associated with CFS is a function of activated immuno-inflammatory, oxidative, and nitrosative stress pathways. These pathways create a vicious cycle where increased ROS generation damages mitochondrial components, further impairing energy production. The elevated ROS levels in CFS patients not only impair mitochondrial function but may also contribute to muscle pain and neural hypersensitivity (13). The combination of pro-inflammatory cytokines, oxidative and nitrosative stress-mediated damage, and deficiency in key antioxidants is responsible for impaired mitochondrial function, including disrupted oxidative phosphorylation and mitochondrial DNA mutation. These mitochondrial disturbances are also directly associated with fatigue and post-exertional malaise in CFS patients (14).

III. CURRENT STANDARDS OF CARE IN CONVENTIONAL MEDICINE

A. Multiple Sclerosis (MS)

The current standard of care for MS emphasizes early and ongoing treatment with disease-modifying therapies (DMTs) to reduce relapses, delay disability progression, and limit new inflammation. The Consortium of Multiple Sclerosis Centers (CMSC) has developed evidence-based clinical practice recommendations recognizing the lifelong nature of the disease and advocating for a multidisciplinary approach to manage each patient living with MS (15).

Treatment Strategy

- Patients diagnosed with active relapsing-remitting MS should begin receiving treatment through the use of DMTs as soon as possible after diagnosis
- Treatment selection must be individualized based on disease activity, preferences of the patient, and risk-benefit benefits
- Disease progression must be monitored through MRI protocols regularly, and through clinical evaluations
- Symptom management shall include management of spasticity, fatigue, pain, and cognition

Treatment should be comprehensive in nature, including physical Therapies, occupational therapies, and psychosocial support

B. Rheumatoid Arthritis (RA)

The American College of Rheumatology (ACR) provides the latest clinical practice guidelines for RA, with the 2021 guidelines representing the current standard of care. The treatment paradigm follows a "treat-to-target" approach aimed at achieving remission or low disease activity (16).

Treatment Approach

- Early diagnosis and immediate application of disease-modifying antirheumatic drugs (DMARDs)
- Conventional synthetic DMARDs (csDMARDs), particularly methotrexate, as first-line of therapy
- Biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) for inadequate responders
- Glucocorticoids for bridging therapy during DMARD initiation or disease flares
- Regular monitoring and treatment adjustments based on disease activity scores
- Conditional recommendations for tapering immunosuppressive therapy after 3-5 years with the goal of discontinuation

C. Fibromyalgia

In the most recent fibromyalgia treatment guidelines, there is an emphasis on using a multi-modal approach that incorporates both pharmacological and non-pharmacological interventions. Currently, there are three medications approved by the FDA as treatments for fibromyalgia: pregabalin (Lyrica), duloxetine (Cymbalta), and milnacipran (Savella). In August 2025, Tonmya (cyclobenzaprine HCl sublingual tablets) became the fourth, FDA-approved medication, marking the first new approval in over 15 years (17).

Standard Treatment Components:

- Exercise is considered the most effective treatment, including yoga, tai chi, and low-impact aerobic activities
- FDA-approved medications targeting pain, sleep, and mood symptoms
- Non-pharmacological approaches, including acupuncture, chiropractic care, and massage therapy
- Psychological interventions for stress management and anxiety
- Patient education and self-management strategies

D. Chronic Fatigue Syndrome (CFS)

CFS currently has no cure available. There are no treatment options approved by the FDA. Instead, CFS is treated through the management of symptoms and helping individuals improve their quality of life through individualized approaches (18).

Current Management Approach:

- Activity Management (Pacing): The cornerstone of treatment, helping patients stay within their "energy envelope" to avoid post-exertional malaise (PEM)
- Sleep Management: Addressing sleep disturbances through sleep hygiene and cautious use of sleep aids
- Pain Management: Using over-the-counter pain relievers first, with specialist referral if needed
- Orthostatic Intolerance Management: Increasing fluid and salt intake, using support stockings, and considering prescription medications
- Cognitive Support: Using organizational tools and cautious use of stimulant medications for concentration issues

IV. FUNCTIONAL NUTRITION-BASED APPROACH

A. Comorbidities and Root Causes

- **Multiple Sclerosis (MS)**

The pathophysiology of MS involves intricate relationships between multiple comorbid conditions and mitochondrial dysfunction. Gaining an understanding of these interrelated pathways can help with both disease development and potential therapeutic interventions.

Insulin Resistance and Metabolic Dysfunction

Insulin resistance is a major comorbidity that advances multiple sclerosis through mitochondrial pathways. Studies show that MS patients are substantially more likely to have metabolic syndrome and insulin resistance than healthy controls. This metabolic disturbance exacerbates cognitive decline in MS patients, particularly affecting verbal memory and spatial comprehension. The connection between insulin resistance and mitochondrial dysfunction creates a vicious cycle where impaired glucose metabolism leads to reduced mitochondrial energy production, which in turn worsens insulin sensitivity (19) (20) (21).

Micronutrient Deficiencies

Vitamin B12 deficiency, frequently observed in MS patients and possibly linked to vitamin D deficiency, contributes significantly to mitochondrial dysfunction and impaired myelin synthesis. This deficiency might exacerbate MS progression or hinder recovery through disrupted mitochondrial metabolic pathways. Low vitamin B12 levels in MS patients highlight a potential causal relationship rather than coincidence (22) (23).

Gut Microbiome Alterations

Another important route in the pathophysiology of MS is the crosstalk between the gut microbiota and mitochondria. Research suggests that changes in the gut microbiota and their interplay with mitochondrial function play a crucial role in the development of disease. Mitochondrial dysfunction may result from changes in the composition and function of the gut microbiota brought on by micronutrient deficiencies. Through metabolite production and immunomodulation, gut dysbiosis affects mitochondrial health in a complex network created by these microbial alterations (24).

Circadian Rhythm and Sleep Disturbances

Patients with MS frequently experience sleep disturbances related to circadian disruption, which impairs their quality of life and exacerbates symptoms of the disease. These disruptions may actively contribute to the pathophysiology and symptom burden of MS rather than being merely secondary effects. Lesion load, medication side effects, and pro-inflammatory cytokines are all part of the pathophysiology. These factors play a part in altered circadian rhythm and disturbed sleep-wake cycles. Besides, circadian rhythm disruptions may contribute to the progression of MS by causing inflammation and metabolic issues (25) (26).

- **Rheumatoid Arthritis (RA)**

The pathogenesis of RA involves complex interactions between genetic, hormonal, environmental, and lifestyle risk factors.

Genetic Predisposition

Genetic factors constitute a substantial portion of RA risk, with the shared epitope recognised as a critical genetic element that affects disease susceptibility. These genetic factors work with environmental triggers to start the autoimmune process.

Environmental Triggers

Environmental factors such as climate change, pollution, and pathogenic microbes can result in chronic diseases, including RA. A correlation was found to exist between air pollution and the severity of RA, with exposure to elevated levels of air pollutants linked to increased hsCRP levels and disease flare. Various pathogens in the environment may induce autoimmunity via molecular mimicry, epitope spreading, bystander activation, and subdominant cryptic antigens (27).

Lifestyle and Metabolic Factors

Obesity: Pro-inflammatory mechanisms induced by obesity play a substantial role in the pathogenesis of RA through chronic inflammation and metabolic dysregulation. The relationship between obesity and RA seems to be especially complicated in women, with obesity influencing RA development primarily among women who smoke (28).

Diet and Microbiome: Changes in diet and gut microbiome are emerging risk factors associated with RA. Microbiome dysbiosis seems to play a key role in RA pathogenesis, potentially through complex interactions with obesity and inflammatory processes. These microbial alterations may initiate immune responses that result in joint inflammation (29).

Hormonal Factors

Sex Hormones: Sex-specific hormonal differences play a significant role in RA pathogenesis. Estrogen is studied to have protective effects in premenopausal women, while early menopause increases disease risk. In men, lower testosterone levels and altered hormone balance may contribute to RA development. These hormonal influences explain, in part, why RA is more common in women than men (30) (31).

- **Fibromyalgia**

Fibromyalgia is frequently associated with several comorbidities that contribute to its pathogenesis through mitochondrial dysfunction pathways.

Insulin Resistance and Metabolic Dysfunction

Insulin resistance represents a significant comorbidity in fibromyalgia, with studies showing that FM severity correlates with variations in insulin resistance indices. The underlying mechanism involves mitochondrial dysfunction and oxidative stress, where impaired glucose metabolism leads to reduced mitochondrial energy production. This

metabolic disturbance creates a vicious cycle where energy failure exacerbates pain and fatigue symptoms characteristic of fibromyalgia (32).

Gut Microbiome Alterations

Gastrointestinal manifestations are prevalent in fibromyalgia patients, with elevated comorbidities like irritable bowel syndrome and gut-brain axis alterations serving as contributing factors. The gut microbiome-mitochondria crosstalk represents a critical pathway where dysbiosis influences mitochondrial health through metabolite production and immune modulation. These microbial changes can produce metabolites that directly impair mitochondrial function or trigger inflammatory responses that damage mitochondria (33).

Thyroid Dysfunction

Thyroid dysfunction, particularly hypothyroidism, is strongly linked to fibromyalgia, with up to 15% of hypothyroidism patients developing fibromyalgia. The mechanism involves intracellular hormone imbalances that disrupt mitochondrial energy production and cellular metabolism. Thyroid hormones are essential for mitochondrial biogenesis and function, and their deficiency leads to impaired oxidative phosphorylation and reduced ATP production (34).

Sleep and Circadian Rhythm Disorders

Sleep disturbances and circadian rhythm disruptions are pronounced in fibromyalgia patients, characterized by abnormalities in melatonin and cortisol secretion. These hormonal disruptions, which are strongly influenced by the circadian pacemaker, directly affect mitochondrial function. The resulting sleep-wake cycle disturbances exacerbate mitochondrial dysfunction through increased oxidative stress and impaired cellular repair mechanisms (35).

- **Chronic Fatigue Syndrome (CFS)**

CFS frequently coexists with several medical conditions that share common pathophysiological mechanisms, creating a complex clinical picture that complicates diagnosis and treatment.

Fibromyalgia

Fibromyalgia is frequently found as a co-existing condition with CFS, wherein both conditions share similar symptoms, including but not limited to chronic pain, fatigue, and sleep difficulties. Fibromyalgia and CFS have a variety of common pathophysiological mechanisms such as central sensitization, autonomic dysregulation, and disrupted pain

processing pathways. Both fibromyalgia and CFS demonstrate impaired stress response systems and altered neurotransmitter function, particularly in serotonin and norepinephrine pathways.

Gastrointestinal dysfunction

A number of people suffering from CFS experience GI dysfunction, and approximately 50% of all CFS patients have IBS. The present state of research regarding the gut-brain axis demonstrates abnormalities stemming from an imbalance in the gut microbiota, increased permeability of the intestinal walls (gut leaks) and hypersensitive viscera, which are implicated in the development of both CFS and IBS. The CFS patient's autonomic nervous system also demonstrates a dysregulation of GI motility and sensitivity which results in a bidirectional relationship between gastrointestinal symptoms and central fatigue mechanisms for the patient.

Thyroid Dysfunction

A significant portion of CFS patients are affected by thyroid dysfunction of which hypothyroidism represents the majority. Thyroid hormones are critical to normal mitochondrial function and cellular energy production, and low levels of thyroid hormones will often intensify fatigue symptoms due to the role of thyroid hormones in oxidative phosphorylation (cellular respiration) and ATP (energy) production.

A. Biomarkers

Disease	Biomarker	Significance	Availability in India
Multiple Sclerosis (MS)	Oligoclonal Bands (OCBs)	Indicates immune activity in the brain/spine (standard for MS)	Yes (Hospitals/Large Labs)
	Neurofilament Light (NfL)	Measures active nerve damage; used to track disease progression	Yes (Premium labs and Hospitals like Hinduja Hospital, Mahim)

	AQP4 / MOG Antibodies	Used to differentiate MS from neuromyelitis optica (NMO)	Yes (Commonly available)
Rheumatoid Arthritis (RA)	Anti-CCP (ACPA)	Highly specific for RA; identifies the disease even in early stages	Yes (Widely available)
	Rheumatoid Factor (RF)	General screening; common but less specific than Anti-CCP.	Yes (Widely available)
	14-3-3η (Eta) Protein	Identifies early erosive joint damage in "seronegative" cases	Yes (Available in Agilus Diagnostics)
Fibromyalgia	Fibromyalgia Panel	Include tests to rule out other health conditions	Yes (Widely available)
	Vitamin B12 & D3	Crucial to rule out "Pseudo-Fibromyalgia" caused by a deficiency	Yes (Widely available)
	hsCRP & ESR	Checks for inflammation to rule out inflammatory arthritis	Yes (Widely available)
Chronic Fatigue Syndrome (CFS)	3D Genomic Test (EpiSwitch)	New test checking DNA folding; 96% accuracy for CFS	No
	Epstein-Barr Virus /Cytomegalovirus Antibodies	Checks if a past viral infection is the trigger for chronic exhaustion	Yes (Commonly available)
	Cortisol	Rules out adrenal issues as the cause of severe fatigue	Yes (Widely available)

Table 1: List of Biomarkers with their Significance and Availability

B. Functional Nutrition-Based Strategy

Anti-Inflammatory Dietary Patterns

All four conditions respond positively to anti-inflammatory dietary patterns, particularly the Mediterranean diet and modified Paleolithic approaches. These diets emphasize reduced intake of salt, animal fat, and dairy while increasing consumption of fruits and vegetables rich in antioxidants and polyphenols. Such dietary patterns help mitigate the inflammatory processes that drive disease progression while supporting mitochondrial health across all conditions.

Mitochondrial-Supportive Nutrients

Specific nutrients play crucial roles in mitochondrial function and are beneficial across all four conditions:

- Omega-3 fatty acids: Demonstrate anti-inflammatory properties and support membrane integrity in neurological, immune, and musculoskeletal tissues
- B-vitamins: Particularly vitamin B12 and folate, are essential for mitochondrial energy production and cellular repair mechanisms
- Coenzyme Q10: Supports electron transport chain function and reduces oxidative stress, addressing the mitochondrial dysfunction that underlies disease progression
- Antioxidants: Including vitamin C, vitamin E, and polyphenols, help neutralize ROS and protect mitochondrial components from oxidative damage

Metabolic Reprogramming Strategies

Functional nutrition approaches focus on metabolic reprogramming to restore mitochondrial function:

- Ketogenic and low-glycemic diets: Help improve mitochondrial efficiency and reduce oxidative stress
- Intermittent fasting: Promotes mitochondrial biogenesis and enhances cellular repair mechanisms
- Targeted supplementation: Including magnesium, alpha-lipoic acid, and acetyl-L-carnitine to support mitochondrial enzyme function and energy production

Functional Foods and Phytonutrients

Specific functional foods show promising results in all four conditions, especially in the case of RA management. Turmeric (curcumin), ginger, and cinnamon contain compounds that regulate inflammation and address cellular dysfunction. These

phytonutrients work through multiple mechanisms, including inhibition of inflammatory pathways and support of mitochondrial function.

Targeted Nutrient Combinations

Specific nutrient combinations show promise in fibromyalgia management. Acetyl-L-carnitine, combined with CoQ10 and other mitochondrial-supportive nutrients, can improve energy production and reduce symptoms. Additionally, vitamins C and E provide antioxidant protection for mitochondrial membranes

Personalization Based on Condition

While the foundation remains consistent, interventions are tailored to address condition-specific needs. MS patients may emphasize myelin-supportive nutrients, RA patients focus on anti-inflammatory compounds, fibromyalgia patients target pain modulation, and CFS patients prioritize energy restoration

V. CONCLUSION

The recognition of mitochondrial dysfunction as a unique pathophysiological mechanism across Multiple Sclerosis, rheumatoid arthritis, Fibromyalgia, and Chronic Fatigue Syndrome provides a rational basis for integrated therapeutic approaches. Functional nutrition strategies that target mitochondrial health, reduce oxidative stress, and modulate inflammation offer a promise for managing all four conditions through their shared pathophysiological pathways. This approach represents a paradigm shift from disease-specific symptom management to addressing the fundamental bioenergetic impairment that underlies these complex chronic conditions. By focusing on the common mitochondrial foundation, functional nutrition provides a comprehensive framework for improving patient outcomes across diverse clinical presentations while addressing the root causes of disease. Studies have demonstrated that dietary interventions can significantly impact disease progression and symptom management across all four conditions. Research shows that functional nutrition approaches reduce fatigue, improve functional disability, and enhance quality of life by addressing mitochondrial dysfunction and reducing inflammatory burden. These interventions work primarily by addressing the common mitochondrial dysfunction and reducing the inflammatory burden, thereby improving patients' quality of life and functional capacity.

REFERENCES

1. San-Millán, I. (2023). The Key Role of Mitochondrial Function in Health and Disease. *Antioxidants*, *12*(4), 782. https://doi.org/10.3390/antiox12040782

2. https://www.who.int/news-room/fact-sheets/detail/multiple-sclerosis

3. https://atlasofms.org/map/global/epidemiology/number-of-people-with-ms

4. https://www.who.int/news-room/fact-sheets/detail/rheumatoid-arthritis

5. Bhargava J, Goldin J. Fibromyalgia. [Updated 2025 Jan 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK540974/

6. Ali SA, Kheirabadi D. Chronic Fatigue Syndrome. [Updated 2025 Dec 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557676/

7. Tschopp, R., König, R. S., Rejmer, P., & Paris, D. H. (2023). Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A preliminary survey among patients in Switzerland. *Heliyon*, *9*(5). https://doi.org/10.1016/j.heliyon.2023.e15595

8. Macchi, C., Giachi, A., Fichtner, I. et al. Mitochondrial function in patients affected with fibromyalgia syndrome is impaired and correlates with disease severity. Sci Rep 14, 30247 (2024). https://doi.org/10.1038/s41598-024-81298-x

9. Gerdle B, Ghafouri B, Lund E, Bengtsson A, Lundberg P, Ettinger-Veenstra Hv, Leinhard OD, Forsgren MF. Evidence of Mitochondrial Dysfunction in Fibromyalgia: Deviating Muscle Energy Metabolism Detected Using Microdialysis and Magnetic Resonance. Journal of Clinical Medicine. 2020; 9(11):3527. https://doi.org/10.3390/jcm9113527

10. Beyaztas, H., Aktas, S., Guler, E. M., & Ata, E. (2023). Oxidative stress may be a contributing factor in fibromyalgia patients' pain mechanisms. Reumatismo, 75(3). https://doi.org/10.4081/reumatismo.2023.1550

11. Sweetman, E., Kleffmann, T., Edgar, C. et al. A SWATH-MS analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome peripheral blood mononuclear cell proteomes reveals mitochondrial dysfunction. J Transl Med 18, 365 (2020). https://doi.org/10.1186/s12967-020-02533-3

12. Missailidis D, Annesley SJ, Allan CY, Sanislav O, Lidbury BA, Lewis DP, Fisher PR. An Isolated Complex V Inefficiency and Dysregulated Mitochondrial Function in Immortalized Lymphocytes from ME/CFS Patients. *International Journal of Molecular Sciences*. 2020; 21(3):1074. https://doi.org/10.3390/ijms21031074

13. Meeus, M., Nijs, J., Hermans, L., Goubert, D., & Calders, P. (2013). The role of mitochondrial dysfunctions due to oxidative and nitrosative stress in the chronic pain or chronic fatigue syndromes and fibromyalgia patients: peripheral and central mechanisms as therapeutic targets? Expert Opinion on Therapeutic Targets, 17(9), 1081–1089. https://doi.org/10.1517/14728222.2013.818657

14. Morris, G., Maes, M. Mitochondrial dysfunctions in Myalgic Encephalomyelitis / chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. *Metab Brain Dis* 29, 19–36 (2014). https://doi.org/10.1007/s11011-013-9435-x

15. https://www.mscare.org/cmsc-recommendations-for-care/

16. Fraenkel, L., Bathon, J. M., England, B. R., St. Clair, E. W., Arayssi, T., Carandang, K., ... & Akl, E. A. (2021). 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis & Rheumatology*, *73*(7), 1108-1123. https://doi.org/10.1002/acr.24596

17. Zhang, Z., Zhou, P., He, N., Wu, Z., Bo, S., Chen, C., Chi, S., Hou, N., Hu, J., Jing, F., Li, B., Li, L., Li, S., Li, Y., Lin, Y., Luo, Q., Mai, J., Mu, R., Ouyang, R., Qin, W., … Zhai, S. (2025). Patient Version of Guideline for Fibromyalgia (2025 Edition). Journal of evidence-based medicine, 18(4), e70094. https://doi.org/10.1111/jebm.70094

18. https://www.cdc.gov/me-cfs/management/index.html

19. Impact of insulin resistance and metabolic syndrome on disability in patients with multiple sclerosis, Rasha Hassan Soliman et al., 2020, The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, https://doi.org/10.1186/s41983-020-0155-y

20. Insulin resistance is associated with cognitive dysfunction in Multiple Sclerosis patients: a cross-sectional study, Hormoz Ayromlou et al., 2023, Journal of Neuroendocrinology, https://doi.org/10.1111/jne.13288

21. Mitochondrial Dysfunction and Multiple Sclerosis, Isabella Peixoto de Barcelos et al., 2019, Biology, https://doi.org/10.3390/biology8020037

22. Multiple sclerosis and vitamin B12 metabolism, E.H. Reynolds, 1992, Journal of Neuroimmunology, https://doi.org/10.1016/0165-5728(92)90137-a

23. Vitamin B12, demyelination, remyelination and repair in multiple sclerosis, Ariel Miller et al., 2005, Journal of the Neurological Sciences, https://doi.org/10.1016/j.jns.2005.03.009

24. The role of the "gut microbiota-mitochondria" crosstalk in the pathogenesis of multiple sclerosis, Huan Tian et al., 2024, Frontiers in Microbiology, https://doi.org/10.3389/fmicb.2024.1404995

25. Sleep Abnormalities in Multiple Sclerosis, Giorgos K. Sakkas et al., 2019, Current Treatment Options in Neurology, https://doi.org/10.1007/s11940-019-0544-7

26. Multiple sclerosis and circadian rhythms: Can diet act as a treatment?, Olga Pivovarova-Ramich et al., 2023, Acta Physiologica, https://doi.org/10.1111/apha.13939

27. Epidemiology and Risk Factors for Rheumatoid Arthritis Development, Aliki I Venetsanopoulou et al., 2023, Mediterranean Journal of Rheumatology, https://doi.org/10.31138/mjr.301223.eaf

28. Interplay between obesity and smoking with regard to RA risk, Anna Karin Hedström et al., 2019, RMD Open, https://doi.org/10.1136/rmdopen-2018-000856

29. Microbiome-based mechanisms hypothesized to initiate obesity-associated rheumatoid arthritis, Y. Luo et al., 2018, Obesity Reviews, https://doi.org/10.1111/obr.12671

30. The role of testosterone and other hormonal factors in the development of rheumatoid arthritis, Carl Turesson et al., 2014, International Journal of Clinical Rheumatology, https://doi.org/10.2217/ijr.13.63

31. Anti-TNF and Sex Hormones, Maurizio Cutolo et al., 2006, Annals of the New York Academy of Sciences, https://doi.org/10.1196/annals.1351.037

32. The impact of metabolic health on fibromyalgia: insights from insulin resistance and related indexes, Sibel Tunç Karaman et al., 2024, Postgraduate Medicine, https://doi.org/10.1080/00325481.2024.2439244

33. An insight into the gastrointestinal component of fibromyalgia: clinical manifestations and potential underlying mechanisms, Mahmoud Slim et al., 2014, Rheumatology International, https://doi.org/10.1007/s00296-014-3109-9

34. Fibromyalgia, Thyroid Dysfunction and Treatment Modalities, Michaël Friedman, 2013, Journal of Restorative Medicine, https://doi.org/10.14200/jrm.2013.2.0113

35. Sleep and circadian rhythm disorders in fibromyalgia, PubMed, https://pubmed.ncbi.nlm.nih.gov/11123049/